Last reviewed · How we verify
Inactive Psilocybin therapy — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Inactive Psilocybin therapy (Inactive Psilocybin therapy) — Centre Hospitalier Universitaire de Nīmes.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Inactive Psilocybin therapy TARGET | Inactive Psilocybin therapy | Centre Hospitalier Universitaire de Nīmes | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Inactive Psilocybin therapy CI watch — RSS
- Inactive Psilocybin therapy CI watch — Atom
- Inactive Psilocybin therapy CI watch — JSON
- Inactive Psilocybin therapy alone — RSS
Cite this brief
Drug Landscape (2026). Inactive Psilocybin therapy — Competitive Intelligence Brief. https://druglandscape.com/ci/inactive-psilocybin-therapy. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing